PL4092025T3 - Kompozycja farmaceutyczna tricyklicznego związku będącego podwójnym inhibitorem pde3/pde4 - Google Patents

Kompozycja farmaceutyczna tricyklicznego związku będącego podwójnym inhibitorem pde3/pde4

Info

Publication number
PL4092025T3
PL4092025T3 PL21741236.0T PL21741236T PL4092025T3 PL 4092025 T3 PL4092025 T3 PL 4092025T3 PL 21741236 T PL21741236 T PL 21741236T PL 4092025 T3 PL4092025 T3 PL 4092025T3
Authority
PL
Poland
Prior art keywords
pde3
tricyclic
pharmaceutical composition
inhibitor compound
dual inhibitor
Prior art date
Application number
PL21741236.0T
Other languages
English (en)
Inventor
Miao YANG
Yuanyuan Sun
Wanjing LI
Zhong Xu
Pengyue BAO
Jing Gao
Ping Dong
Hui HUI
Xiongfeng JI
Yunfu Luo
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. filed Critical Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Publication of PL4092025T3 publication Critical patent/PL4092025T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL21741236.0T 2020-01-15 2021-01-15 Kompozycja farmaceutyczna tricyklicznego związku będącego podwójnym inhibitorem pde3/pde4 PL4092025T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010042865 2020-01-15
PCT/CN2021/072145 WO2021143841A1 (zh) 2020-01-15 2021-01-15 三并环类pde3/pde4双重抑制剂化合物的药物组合物

Publications (1)

Publication Number Publication Date
PL4092025T3 true PL4092025T3 (pl) 2024-10-28

Family

ID=76863620

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21741236.0T PL4092025T3 (pl) 2020-01-15 2021-01-15 Kompozycja farmaceutyczna tricyklicznego związku będącego podwójnym inhibitorem pde3/pde4

Country Status (9)

Country Link
US (1) US20230060174A1 (pl)
EP (1) EP4092025B9 (pl)
JP (2) JP7712276B2 (pl)
KR (1) KR20220127845A (pl)
CN (3) CN119909076A (pl)
CA (1) CA3167378A1 (pl)
ES (1) ES2995084T3 (pl)
PL (1) PL4092025T3 (pl)
WO (1) WO2021143841A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4092025T3 (pl) * 2020-01-15 2024-10-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Kompozycja farmaceutyczna tricyklicznego związku będącego podwójnym inhibitorem pde3/pde4
CN114929701B (zh) * 2020-01-15 2024-11-05 正大天晴药业集团股份有限公司 一种pde3/pde4双重抑制剂的结晶及其应用
US20250171436A1 (en) * 2022-01-21 2025-05-29 Xizang Haisco Pharmaceutical Co., Ltd. Tricyclic Fused Heterocyclic PDE3/4 Dual Inhibitor and Use Thereof
CN118105342A (zh) * 2023-09-28 2024-05-31 立生医药(苏州)有限公司 一种含pde-4抑制剂的无菌吸入用混悬液及其制备方法和应用
CN120136868A (zh) * 2023-12-13 2025-06-13 石家庄以岭药业股份有限公司 三环稠杂环类pde3/4双重抑制剂及其制备方法与应用
WO2026052051A1 (zh) * 2024-09-06 2026-03-12 正大天晴药业集团股份有限公司 杂环化合物在治疗肺疾病中的应用
WO2026158380A1 (zh) * 2025-01-21 2026-07-30 正大天晴药业集团股份有限公司 含三并环的化合物的药物组合物
WO2025149100A2 (zh) * 2025-04-29 2025-07-17 北京泰德制药股份有限公司 含有pde4抑制剂化合物a的药物组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI64370C (fi) * 1977-05-05 1983-11-10 Hoechst Ag Foerfarande foer framstaellning av terapeutiskt anvaendbara pyimido-(6,1-a)isokinolin-2-imino-4-onderivat
ZW6284A1 (en) * 1983-05-05 1985-10-30 Hoffmann La Roche Novel pyrimidone derivatives
US6473627B1 (en) 1998-07-22 2002-10-29 Mitsubishi Denki Kabushiki Kaisha Mobile communication system and mobile communication method
DK1165558T3 (da) 1999-03-31 2004-02-09 Vernalis Ltd Pyrimido[6,1-a]isoquinolin-4-on-derivater
CN101262846A (zh) * 2005-07-15 2008-09-10 Map药物公司 在离散的吸入粒子中结合的多种活性药物成分及其制剂
SI2603509T1 (sl) * 2010-08-09 2014-10-30 Verona Pharma Plc Kristalinična oblika spojine PIRIMIDIO(6,1-A) IZOKINOLIN-4-ENA
JP6560986B2 (ja) * 2013-03-15 2019-08-14 ヴェローナ ファーマ ピーエルシー 複合製剤
LT3193835T (lt) * 2014-09-15 2018-06-11 Verona Pharma Plc Skysta inhaliuojama vaisto forma, apimanti rpl554
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
FI3822272T3 (fi) * 2018-07-13 2025-01-21 Chia Tai Tianqing Pharmaceutical Group Co Ltd Fuusioitunut trisyklinen yhdiste PDE3:n/PDE4:n kaksoisinhibiittorina
PL4092025T3 (pl) * 2020-01-15 2024-10-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Kompozycja farmaceutyczna tricyklicznego związku będącego podwójnym inhibitorem pde3/pde4
CN114929701B (zh) * 2020-01-15 2024-11-05 正大天晴药业集团股份有限公司 一种pde3/pde4双重抑制剂的结晶及其应用

Also Published As

Publication number Publication date
JP2025148464A (ja) 2025-10-07
US20230060174A1 (en) 2023-03-02
WO2021143841A1 (zh) 2021-07-22
EP4092025A4 (en) 2023-08-30
EP4092025B1 (en) 2024-08-14
AU2021208129A1 (en) 2022-08-18
CN119792296A (zh) 2025-04-11
CA3167378A1 (en) 2021-07-22
CN114929700B (zh) 2024-11-22
KR20220127845A (ko) 2022-09-20
JP7712276B2 (ja) 2025-07-23
EP4092025A1 (en) 2022-11-23
CN119909076A (zh) 2025-05-02
EP4092025B9 (en) 2024-11-06
CN114929700A (zh) 2022-08-19
ES2995084T3 (en) 2025-02-05
JP2023512475A (ja) 2023-03-27

Similar Documents

Publication Publication Date Title
EP4092025A4 (en) PHARMACEUTICAL COMPOSITION OF A TRICYCLIC PDE3/PDE4 DOUBLE INHIBITOR COMPOUND
IL280075A (en) Fused tri-cyclic compound as pde3/pde4 dual inhibitor
IL310442A (en) FUSED BICYCLIC heteroaryl compounds are useful as NLRP3 inhibitors
AU2024303288A1 (en) Parp1 inhibitor compounds
EP2244574A4 (en) TRICYCLIC COMPOUNDS AS MODULATORS OF TNF SYNTHESIS AND AS PDE4 INHIBITORS
EP4076395A4 (en) INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS
NZ730134A (en) Substituted tricyclic compounds as fgfr inhibitors
EP4137484A4 (en) TRICYCLIC COMPOUNDS AS EGFR INHIBITORS
IL319360A (en) Novel compounds as modulators of NLRP3 inhibition
AU2024255473A1 (en) Pyrazolopyrimidine derivatives as inhibitors of nlrp3
IL317506A (en) Tricyclic triazole compounds as fish oil inhibitors
ZA202110347B (en) Bicyclic compound as rip-1 kinase inhibitor and application thereof
EP4293018A4 (en) COMPOUND AS NLRP3 INHIBITOR
AU2024356450A1 (en) Parp1 inhibitor compounds
AU2024354981A1 (en) Parp1 inhibitor compounds
AU2022211285A9 (en) Tricyclic compounds as anticancer agents
HK40106117A (en) Tricyclic compounds as inhibitors of kras
HK40083546A (en) Tricyclic compounds as inhibitors of kras
IL326691A (en) Tricyclic heteroaromatic inhibitors of klk5
CA3273582A1 (en) Novel compounds as modulators of nlrp3 inhibition
CA3302937A1 (en) Tricyclic heteroaromatic inhibitors of klk5
CA3288941A1 (en) Pyrazolopyrimidine derivatives as inhibitors of nlrp3
IL321066A (en) Processes for preparing NLRP3 inhibitor
CA3284710A1 (en) Substituted nitrogen-containing tricyclic compounds as parp inhibitors and the use thereof
HK40109676A (en) Inhibitors of nlrp3